<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>NOPR Collection:</title>
    <link>http://nopr.niscpr.res.in/handle/123456789/18005</link>
    <description />
    <pubDate>Sat, 10 Oct 2026 14:15:15 GMT</pubDate>
    <dc:date>2026-10-10T14:15:15Z</dc:date>
    <item>
      <title>Spectrophotometric method for the simultaneous determination of piroxicam and 2-aminopyridine</title>
      <link>http://nopr.niscpr.res.in/handle/123456789/18085</link>
      <description>Title: Spectrophotometric method for the simultaneous determination of piroxicam and 2-aminopyridine
Authors: Suntornsuk, L; Bunavitayakij, P; Pitayatienanan, P
Abstract: A&#xD;
rapid and simple spectrophotometric method is proposed for the simultaneous determination&#xD;
of piroxicam (Pi) and 2-aminopyridine (2-Ap). Piroxicam is stable under basic hydrolysis,&#xD;
but yields 2-Ap as one of the degradation products under acid hydrolysis. The&#xD;
method is based on the measurement of absorbances of 2-Ap and Pi at 300 and 360&#xD;
nm, respectively, and the calculations are based on the binary method. The&#xD;
absorbances of both compounds obey Beer-Lambert 's law over the concentration range&#xD;
of 5-25 µg L&lt;sup&gt;-1&lt;/sup&gt;&#xD;
with good linearity (&lt;i style="mso-bidi-font-style:normal"&gt;r&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;&gt;0.99).&#xD;
The recoveries are with in 100.8- 106.4% for Pi and are within 96.4-98.9% for&#xD;
2- Ap. Precision is good with acceptable limits of detection (LOD) and&#xD;
quantitation (LOQ) for both compounds. The method has been applied for the&#xD;
determination of Pi and 2-Ap in piroxicam capsules. The average content of two&#xD;
different brands of piroxicam is 97.4 and 98.5% (n = 3), which complies with&#xD;
the USP 26 (92.5- 107.5%). Under the stress condition (refluxing with 0.1 &lt;i&gt;N &lt;/i&gt;HCI),&#xD;
the percentages of piroxicam decrease from 100% (0 h) to 18.9% (21 h) and 2-Ap&#xD;
increase from 0% (0 h) to 63.6% (21 h).
Page(s): 737-740</description>
      <pubDate>Fri, 01 Apr 2005 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://nopr.niscpr.res.in/handle/123456789/18085</guid>
      <dc:date>2005-04-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Determination of free and total zinc using 2-[(5-bromo-2-pyridylazo)]- 5-diethylaminophenol in mixed surfactant medium</title>
      <link>http://nopr.niscpr.res.in/handle/123456789/18084</link>
      <description>Title: Determination of free and total zinc using 2-[(5-bromo-2-pyridylazo)]- 5-diethylaminophenol in mixed surfactant medium
Authors: Banjare, Ravi Kumar; Thakur, Manisha; Deb, Manas Kanti
Abstract: A simple&#xD;
and sensitive spectrophotometric method for chemical fractionation and determination&#xD;
of zinc in cosmetics and pharmaceuticals is described based on the formation or&#xD;
red coloured species of Zn(II) with 2-[(5-bromo-2-pyridylazo)]-5-diethylaminophenol&#xD;
(5-Br-PADAP) and mixed surfactants (TX-100 and Brij-35) in the &lt;i style="mso-bidi-font-style:normal"&gt;p&lt;/i&gt;H range 8.2- 10.5. The red coloured Zn(II)-5-Br-PADAP-(TX-100+Brij-35)&#xD;
complex in aqueous medium shows maximum absorbance at 550 mm with molar&#xD;
&#xD;
absorptivity&#xD;
of 1.60&lt;img src='/image/spc_char/cross.gif' border=0&gt;10&lt;sup&gt;5&lt;/sup&gt;&#xD;
dm&lt;sup&gt;3&lt;/sup&gt; mol&lt;sup&gt;-1&lt;/sup&gt;  cm&lt;sup&gt;-l&lt;/sup&gt;.&#xD;
The detection limit or the method is 6 ng  Zn(II)/cm&lt;sup&gt;2&lt;/sup&gt; and obeys Beer's law up&#xD;
to 0.4 µg Zn(II)/cm&lt;sup&gt;2&lt;/sup&gt; in aqueous phase. Relative standard deviation for&#xD;
ten determinations for solution containing 0.2 µg Zn(II)/cm&lt;sup&gt;2&lt;/sup&gt; is 1.5%.&#xD;
The validity of the method has been satisfactorily examined for the&#xD;
determination of zinc (free and total) in cosmetics and pharmaceutical&#xD;
formulating samples manufactured in India, with RSD value from actual analyte&#xD;
content ranging between 2.1 and 2.7% for cosmetics and between 1.9 and 2.8 %&#xD;
for pharmaceutical formulations.&#xD;
&#xD;
&lt;/span&gt;
Page(s): 733-736</description>
      <pubDate>Fri, 01 Apr 2005 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://nopr.niscpr.res.in/handle/123456789/18084</guid>
      <dc:date>2005-04-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Synthesis and characterisation of 5,6- bis(salicylideneimino )-1,10-phenanthroline and its trinuclear complexes</title>
      <link>http://nopr.niscpr.res.in/handle/123456789/18083</link>
      <description>Title: Synthesis and characterisation of 5,6- bis(salicylideneimino )-1,10-phenanthroline and its trinuclear complexes
Authors: Demirhan, Nebahat; Avclata, Ulvi; Gul, Ahmet
Abstract: As a&#xD;
multidonor ligand with phenanthroline and salicylaldimine functionalities on&#xD;
the same molecule, 5,6-bis(salicylideneimino)-1,10-phenanthroline (LH&lt;sub&gt;2&lt;/sub&gt;)&#xD;
has been&#xD;
&#xD;
synthesized&#xD;
by the reaction of 5,6-diamino-1,10-phenanthroline with salicylaldehyde and its&#xD;
metal complexes with Ni(II) and Cu(II) have been prepared. Both of the isolated&#xD;
complexes are trinuclear with metal ligand ratio of 3:2. Protonation constants&#xD;
of LH&lt;sub&gt;2&lt;/sub&gt; which have been determined by potentiometric titration in solution&#xD;
are log &lt;i&gt;K&lt;/i&gt;&lt;sub&gt;&lt;span style="mso-bidi-font-style:italic"&gt;1&lt;/span&gt;&lt;/sub&gt;&lt;i&gt;=&lt;/i&gt;&lt;span style="mso-bidi-font-style:italic"&gt;8.96&lt;i&gt;, &lt;/i&gt;log &lt;i&gt;K&lt;/i&gt;&lt;sub&gt;&lt;span style="mso-bidi-font-style:italic"&gt;2&lt;/span&gt;&lt;/sub&gt;&lt;i&gt;=&lt;/i&gt;&lt;span style="mso-bidi-font-style:italic"&gt;15. 88&lt;i&gt;, &lt;/i&gt;log &lt;i&gt;K&lt;/i&gt;&lt;sub&gt;&lt;span style="mso-bidi-font-style:italic"&gt;3&lt;/span&gt;&lt;/sub&gt;&lt;i&gt;=&lt;/i&gt;&lt;span style="mso-bidi-font-style:italic"&gt;8.73&lt;i&gt; &lt;/i&gt;and log &lt;i&gt;K&lt;/i&gt;&lt;sub&gt;&lt;span style="mso-bidi-font-style:italic"&gt;4&lt;/span&gt;&lt;/sub&gt;&lt;i&gt;=&lt;/i&gt;&lt;span style="mso-bidi-font-style:italic"&gt;2.78&lt;i&gt;. &lt;/i&gt;The newly synthesized compounds&#xD;
have been verified by IR, &lt;sup&gt;1&lt;/sup&gt;H NMR and mass spectra together with&#xD;
elemental analysis.&#xD;
&#xD;
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
Page(s): 729-732</description>
      <pubDate>Fri, 01 Apr 2005 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://nopr.niscpr.res.in/handle/123456789/18083</guid>
      <dc:date>2005-04-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Reactions of [(µ-H) Os&lt;sub&gt;3&lt;/sub&gt;(CO)&lt;sub&gt;8&lt;/sub&gt;- {Ph&lt;sub&gt;2&lt;/sub&gt;PCH&lt;sub&gt;2&lt;/sub&gt;P(Ph)C&lt;sub&gt;6&lt;/sub&gt;H&lt;sub&gt;4&lt;/sub&gt;}] and [Os&lt;sub&gt;3&lt;/sub&gt;(CO)&lt;sub&gt;10&lt;/sub&gt; (µ-dppm)] with 2-mercaptoimidozole, 2-mercaptobenzimidazole and 2-mercaptobenzothiazole: X-ray structure of [(µ-H)Os&lt;sub&gt;3&lt;/sub&gt;(CO)&lt;sub&gt;8&lt;/sub&gt;(µ-dppm)(µ-η&lt;sup&gt;1&lt;/sup&gt;-SN&lt;sub&gt;2&lt;/sub&gt;C&lt;sub&gt;3&lt;/sub&gt;H&lt;sub&gt;3&lt;/sub&gt;)]</title>
      <link>http://nopr.niscpr.res.in/handle/123456789/18082</link>
      <description>Title: Reactions of [(µ-H) Os&lt;sub&gt;3&lt;/sub&gt;(CO)&lt;sub&gt;8&lt;/sub&gt;- {Ph&lt;sub&gt;2&lt;/sub&gt;PCH&lt;sub&gt;2&lt;/sub&gt;P(Ph)C&lt;sub&gt;6&lt;/sub&gt;H&lt;sub&gt;4&lt;/sub&gt;}] and [Os&lt;sub&gt;3&lt;/sub&gt;(CO)&lt;sub&gt;10&lt;/sub&gt; (µ-dppm)] with 2-mercaptoimidozole, 2-mercaptobenzimidazole and 2-mercaptobenzothiazole: X-ray structure of [(µ-H)Os&lt;sub&gt;3&lt;/sub&gt;(CO)&lt;sub&gt;8&lt;/sub&gt;(µ-dppm)(µ-η&lt;sup&gt;1&lt;/sup&gt;-SN&lt;sub&gt;2&lt;/sub&gt;C&lt;sub&gt;3&lt;/sub&gt;H&lt;sub&gt;3&lt;/sub&gt;)]
Authors: Begum, Noorjahan; Hassan, Md Manjur; Hossain, G M Golzar; Kabir, Shariff E
Abstract: The&#xD;
electron-deficient compound [(µ-H)Os&lt;sub&gt;3&lt;/sub&gt;(CO)&lt;sub&gt;8&lt;/sub&gt;-{Ph&lt;sub&gt;2&lt;/sub&gt;PCH&lt;sub&gt;2&lt;/sub&gt;P(Ph)C&lt;sub&gt;6&lt;/sub&gt;H&lt;sub&gt;4&lt;/sub&gt;}]&#xD;
&lt;b style="mso-bidi-font-weight:normal"&gt;2&lt;/b&gt; reacts with 2-mercaptoimidozole,&#xD;
2- mercaptobenzimidazole and 2-mercaptobenzothiazole at 80°C to give [(µ-H)Os&lt;sub&gt;3&lt;/sub&gt;(CO)&lt;sub&gt;8&lt;/sub&gt;(µ-dppm)(µ-η&lt;sup&gt;1&lt;/sup&gt;-SN&lt;sub&gt;2&lt;/sub&gt;C&lt;sub&gt;3&lt;/sub&gt;H&lt;sub&gt;3&lt;/sub&gt;)]&#xD;
&lt;b style="mso-bidi-font-weight:normal"&gt;3&lt;/b&gt;, [(µ-H)Os&lt;sub&gt;3&lt;/sub&gt;(CO)&lt;sub&gt;8&lt;/sub&gt;(µ-dppm)(µ-η&lt;sup&gt;1&lt;/sup&gt;-SN&lt;sub&gt;2&lt;/sub&gt;C&lt;sub&gt;7&lt;/sub&gt;H&lt;sub&gt;5&lt;/sub&gt;)]&#xD;
4 and [(µ-H)Os&lt;sub&gt;3&lt;/sub&gt;(CO)&lt;sub&gt; 8&lt;/sub&gt;(µ-dppm)(µ-η&lt;sup&gt;1&lt;/sup&gt;-SN&lt;sub&gt;2&lt;/sub&gt;C&lt;sub&gt;7&lt;/sub&gt;H&lt;sub&gt;5&lt;/sub&gt;)]&#xD;
&lt;b style="mso-bidi-font-weight:normal"&gt;5&lt;/b&gt; in 30, 50 and 59% yields,&#xD;
respectively. The compounds are formed by the oxidative addition of S-H bond followed&#xD;
by demetallation of the phenyl ring of the orthometallated dppm ligand.&#xD;
Compounds &lt;b style="mso-bidi-font-weight:normal"&gt;3-5&lt;/b&gt; have also been&#xD;
obtained from the reactions of [Os&lt;sub&gt;3&lt;/sub&gt;(CO)&lt;sub&gt;10&lt;/sub&gt;(µ-dppm)] &lt;b style="mso-bidi-font-weight:normal"&gt;1&lt;/b&gt; with 2- mercaptoimidozole,&#xD;
2-mercaptobenzimidazole and 2- mercaptobenzothiazole, respectively at 110ºC but&#xD;
in some what lower yields. The compounds have been characterized by elemental analysis,&#xD;
IR, &lt;sup&gt;I&lt;/sup&gt;H NMR and &lt;sup&gt;31&lt;/sup&gt;p{&lt;sup&gt;1&lt;/sup&gt;H} NMR spectroscopic data&#xD;
together with single crystal X-ray diffraction studies for &lt;b style="mso-bidi-font-weight:&#xD;
normal"&gt;3&lt;/b&gt;. Compound &lt;b style="mso-bidi-font-weight:normal"&gt;3&lt;/b&gt;&#xD;
crystallizes in the triclinic space group &lt;i&gt;PI &lt;/i&gt;with &lt;i style="mso-bidi-font-style:&#xD;
normal"&gt;a&lt;/i&gt;=11.3453(12), &lt;i style="mso-bidi-font-style:normal"&gt;b&lt;/i&gt;=13.651(2),&#xD;
&lt;i style="mso-bidi-font-style:normal"&gt;c&lt;/i&gt;=15.069(2) Å, α=84.709(l1), &lt;span style="font-family:Symbol;mso-ascii-font-family:" times="" new="" roman";mso-fareast-font-family:="" hiddenhorzocr;mso-hansi-font-family:"times="" roman";mso-char-type:symbol;="" mso-symbol-font-family:symbol"=""&gt;b=72.7C6(9),&#xD;
γ=68.265(9)º, Z=2 and &lt;i&gt;V&lt;/i&gt;&lt;span style="mso-bidi-font-style:italic"&gt;=2069.5(4)&lt;i&gt;&#xD;
&lt;/i&gt;Å&lt;sup&gt;3&lt;/sup&gt;. The structure consists of an equilateral triangle of&#xD;
osmium atoms with a bridging dppm, a bridging hydride and a bridging 2- mercaptoimidazolato&#xD;
ligand.&#xD;
&#xD;
&lt;/span&gt;&lt;/span&gt;
Page(s): 723-728</description>
      <pubDate>Fri, 01 Apr 2005 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://nopr.niscpr.res.in/handle/123456789/18082</guid>
      <dc:date>2005-04-01T00:00:00Z</dc:date>
    </item>
  </channel>
</rss>

